These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 11299844

  • 1. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
    Nygård R, Norum J, Due J.
    Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
    [Abstract] [Full Text] [Related]

  • 2. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I, Jelić S, Radosavljević D, Nikolić-Tomasević Z.
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [Abstract] [Full Text] [Related]

  • 3. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
    Fujikawa K, Awakura Y, Okabe T, Watanabe R, Nishimura S.
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
    [Abstract] [Full Text] [Related]

  • 4. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE.
    Cancer; 1996 May 01; 77(9):1854-61. PubMed ID: 8646685
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
    Konski A, Watkins-Bruner D, Brereton H, Feigenberg S, Hanks G.
    Cancer; 2006 Jan 01; 106(1):51-7. PubMed ID: 16323171
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug 01; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 12. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Apr 15; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Economical data and advanced prostate carcinoma: do we need new guidelines for decision making?
    Rohde V, Wellmann A, Fogt F, Weidner W, Katalinic A.
    Oncol Rep; 2002 Apr 15; 9(6):1185-8. PubMed ID: 12375016
    [Abstract] [Full Text] [Related]

  • 16. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
    Lloyd A, Penson D, Dewilde S, Kleinman L.
    Prostate Cancer Prostatic Dis; 2008 Apr 15; 11(2):153-9. PubMed ID: 17637761
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G, Lindsay S, Bowsher WG.
    Prostate Cancer Prostatic Dis; 2003 Apr 15; 6(2):187-9. PubMed ID: 12806381
    [Abstract] [Full Text] [Related]

  • 19. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group.
    de Haes H, Olschewski M, Kaufmann M, Schumacher M, Jonat W, Sauerbrei W, Zoladex Early Breast Cancer Research Association Trialists Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4510-6. PubMed ID: 14610048
    [Abstract] [Full Text] [Related]

  • 20. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer.
    Samant RS, Dunscombe PB, Roberts GH.
    Urol Oncol; 2003 Dec 15; 21(3):171-7. PubMed ID: 12810202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.